title: Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis.
abstract: OBJECTIVE
  Based on former studies in experimental animals on the effect of octreotide on serum and ascitic levels of tumor necrosis factor-alpha and interleukin-6 in the field of necrotizing pancreatitis, the present study was designed to investigate the effect of octreotide on serum interleukin-6 of patients with acute edematous pancreatitis.
  
  
  METHODS
  A total of 36 patients with acute edematous pancreatitis and initiation of symptoms 12 hours before their admission were enrolled in the study; 20 were treated with octreotide 200 microg tid and 16 with octreotide 500 microg tid for five days. Blood was sampled at regular time intervals. Interleukin-6 was determined by an enzyme-immunoassay and C-reactive protein by nephelometry.
  
  
  RESULTS
  Mean concentrations of interleukin-6 of patients treated with octreotide 200 microg tid were 59.52 pg/mL before and 94.08, 46.25, 49.94, 58.16 and 26.08 pg/mL at 3, 6, 24, 48 and 72 hours after the start of therapy respectively. Respective values of patients treated with octreotide 500 microg tid were 57.19, 53.07, 57.83, 36.06, 54.29 and 65.49 pg/mL. Mean C-reactive protein of patients treated with octreotide 200 microg tid were 67.37 mg/L before and 48.51, 106.08 and 95.58 mg/L at 24, 48 and 72 hours after the start of therapy respectively. Respective values of patients treated with octreotide 500 microg tid were 65.51, 60.56, 90.68 and 64.22 mg/L.
  
  
  CONCLUSIONS
  A transient, but not statistically significant, decrease of serum interleukin-6 levels was documented after administration of octreotide in the field of acute edematous pancreatitis. That decrease was earlier after the application of the 500 microg tid dose than the 200 microg tid dose. Studies with a greater number of patients are mandatory to fully clarify the effect of octreotide, if any, on acute pancreatitis.
authors.affiliation: 1st Department of Propaedeutic Medicine, University of Athens, Medical School, Greece.
authors.forename: George C
authors.initials: GC
authors.lastname: Nikou
authors.forename: Evangelos J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Grecka
authors.forename: Ch
authors.initials: Ch
authors.lastname: Toumpanakis
authors.forename: George
authors.initials: G
authors.lastname: Giannikopoulos
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Katsilambros
mesh_terms: D000208:Acute Disease; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007124:Immunoenzyme Techniques; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D015282:Octreotide / Q000008:administration & dosage*; D010195:Pancreatitis / Q000097:blood* / Q000209:etiology; D011446:Prospective Studies
chemical_list: D005765:Gastrointestinal Agents; D015850:Interleukin-6; D002097:C-Reactive Protein; D015282:Octreotide